Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000670357 | SCV000795199 | likely pathogenic | Retinitis pigmentosa 25 | 2017-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001389826 | SCV001591319 | pathogenic | not provided | 2023-05-20 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs764229134, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.His2719Tyrfs*27) in the EYS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 426 amino acid(s) of the EYS protein. This premature translational stop signal has been observed in individuals with recessive retinitis pigmentosa (PMID: 20375346). ClinVar contains an entry for this variant (Variation ID: 554682). This variant is also known as c.8218_8219delCA. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the EYS protein in which other variant(s) (p.Tyr2935*) have been determined to be pathogenic (PMID: 22363543, 24652164, 28763560). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. |
Baylor Genetics | RCV000670357 | SCV004195234 | pathogenic | Retinitis pigmentosa 25 | 2024-03-18 | criteria provided, single submitter | clinical testing | |
Sharon lab, |
RCV001003015 | SCV001161070 | pathogenic | Retinitis pigmentosa | 2019-06-23 | no assertion criteria provided | research | |
Natera, |
RCV000670357 | SCV002083496 | pathogenic | Retinitis pigmentosa 25 | 2020-11-18 | no assertion criteria provided | clinical testing |